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To distinguish carcinoma, either adenocarcinoma (ADC) or
squamous cell carcinoma (SCC), and malignant mesothelioma
(MM) in effusion can be a diagnostic challenge based on mor-
phology alone. This study evaluates the utility of WT-1, p63,
MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immu-
nostains in effusions when ADC and SCC of the lung are in the
differential diagnosis with MM. A cohort of 43 effusions consist-
ing of lung ADC (N ¼ 10), SCC (N ¼ 15), and MM (N ¼ 18,
mostly (16) pleural based), was subjected to immunostains using
the above mentioned antibodies. WT-1 was positive in 100%
MM, 0% ADC, and 0% SCC cases while p63 was positive in
0% MM, 30% ADC, and 80% SCC cases. Stain for MOC31 was
positive in 100% ADC, 67% SCC, and 35% MM cases. Simi-
larly, mesothelin antibody stained 100% ADC, 60% SCC, and
47% MM cases. Antibodies for K903 and CK5/6 stained 100%
SCC cases but fewer ADC cases (40 and 10%, respectively). In
conclusion, in this cohort of mostly pleural malignant effusion,
MM can be identified with positive staining for WT-1 and nega-
tive staining for p63. Conversely, negative staining with WT-1
and positive staining for p63 exclude MM. Used as part of an
immunostain panel, cytokeratin markers (CK5/6 and K903) are
useful in differentiating SCC from ADC when MM is already
excluded, and MOC31 might have limited value in differentiat-
ing ADC from MM. A negative stain with MOC31 can exclude
lung ADC. Mesothelin, on the other hand, is not useful in
the differential diagnosis of ADC, SCC, and MM. Diagn.
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It is difficult to distinguish poorly differentiated carci-
noma of lung, either adenocarcinoma (ADC) or squamous
cell carcinoma (SCC), from malignant mesothelioma
(MM) based on morphology alone in pleural effusion. Af-
ter a diagnosis of malignancy is initially made in effu-
sions, further classification of ADC, SCC, or MM is
needed to help identify the primary tumor and to deter-
mine therapy approaches. In daily pathology practice,
immunocytochemical stains (ICC) play a vital role in aid-
ing differential diagnoses. The most widely used immuno-
panel in surgical and cytology specimens includes calreti-
nin, CEA, BerEP4, CD15 (LeuM1), and cytokeratins.1–4
However, lack of high specificity and sensitivity of these
markers prompted an on going search of better markers.
Newer markers including WT-1, p63, MOC31, and
mesothelin have been described and some have gained ac-
ceptance to be used in practice. Wilms’ tumor susceptibility
gene (WT-1) expression is mostly restricted to mesenchy-
mally derived tissues.5,6 Antibody raised against this gene
product shows strong nuclear stain in mesothelioma cell
lines and in mesothelioma, but not in non-mesothelioma
tumors involving the lung, including non-small cell carcino-
mas examined.6,7 Others, however, did not find WT-1 as a
specific marker for mesothelioma, especially in autopsy
specimens.8 Another antibody that has been described
recently is an antibody against p63, a p53-related gene prod-
uct, which has been shown to be specific for SCC and is con-
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sidered one of the best markers to be used in a panel when
the differential diagnosis is between SCC and MM.9 Simi-
larly, MOC31 and mesothelin have been tested for their util-
ity in the differential diagnosis of MM and shown to be use-
ful in separating lung SCC from MM.10,11 MOC-31 is a
monoclonal antibody that recognizes a transmembrane gly-
coprotein often expressed in epithelial tumors. Mesothelin is
also a glycoprotein that its membrane bound form has been
found expressed in mesothelial cells12 and a commercially
available antibody (5B2) has been applied to paraffin em-
bedded clinical samples.10,11,13 One recent publication
showed MOC31’s utility in separating ADC from reactive
mesothelial cells in pleural effusions (MOC-31 was found to
be 95% sensitive and 100% specific for ADC).14 A more
comprehensive analysis of multiple markers in 30 MM and
30 SCC for their utility demonstrated that 100% of the MM
were positive for calretinin and mesothelin, 93% each for
WT1 and keratin 5/6, 7% each for p63, and MOC-31, and
0% for B72.3, CEA, leu-M1, and TTF-1.9 In this study,
100% of the SCC was positive for p63 and keratin 5/6, 97%
for MOC-31, 77% for CEA, 40% for calretinin, 30% for leu-
M1, 27% for mesothelin, and 0% for WT 1 and TTF-1.9 This
study recommended using a combination of two positive
mesothelioma markers (WT1 and calretinin or mesothelin)
with two negative mesothelioma markers (p63 and MOC-
31) to differentiate between epithelioid mesotheliomas and
SCC of the lung.9 In contrast, a recent study found that
although anti-mesothelin antibody stained mesothelioma
and benign mesothelial cells more frequently than ADC
with statistical significance; however, mesothelin was not a
good marker for mesothelioma with a sensitivity and speci-
ficity of 73% and 55%, respectively, in comparison to calre-
tinin with a sensitivity and specificity of 95% and 86%,
respectively.13 Others further demonstrated that cytokera-
tins, especially CK5/6, were among the markers showing
utility in differentiating MM from other epithelial neo-
plasms.15,16 A recent article systematically analyzed pub-
lished data from 88 papers in order to establish the sensitiv-
ity and specificity of 15 commonly used antibodies in distin-
guishing mesothelioma from lung ADC.2 This analysis
concluded that MOC-31 and BG8 were the most sensitive
antibodies for identifying pulmonary ADC (both with 93%
sensitivity) while monoclonal CEA and TTF-1 were the
most specific (97% and 100% specificity). In their analysis,
CK5/6 and HBME-1 were the most sensitive antibodies for
epithelioid mesothelioma (83% and 85%) and the most spe-
cific antibodies were CK5/6 (85%) and WT-1 (96%).2 How-
ever, it seems not uncommon to have different results from
different studies although a few mesothelial markers, carci-
noma markers, and other miscellaneous markers were con-
sidered most useful in differentiating epithelioid MM from
carcinomas.17
Those studies were mostly performed on surgical speci-
mens. It is known that different types of specimen prepa-
rations influence immunochemical reaction and conse-
quently the utility of immunostains. In addition, the tumor
cells in body effusions may have changed protein
expression profile because of the different molecular sig-
naling in the environment.18–20 Thus, it is necessary to
perform a validation study in order to extend the use of
tumor markers to cytopathology. Furthermore, to our
knowledge, a direct comparison of reactivity for WT-1,
p63, mesothelin, and MOC31 antibodies in effusion to
differentiate ADC, SCC, and MM has not been per-
formed. Recently, we have explored the role of a panel
of 6 antibodies, including antibodies for calretinin, cyto-
keratins, in distinguishing lung ADC and SCC, and MM
in effusions.21 The purpose of the current study was to
extend our previous analysis and to evaluate whether
WT-1, p63, MOC31, mesothelin, and cytokeratin (CK5/6
and K903) have a utility in the diagnosis of malignant
effusions when ADC, SCC, and MM are in the differen-
tial diagnosis.
Materials and Methods
We identified a cohort of malignant effusions consisting
of ADC (10 cases), SCC (15 cases), and MM (18 cases)
in our institution with IRB approval. All the carcinoma
cases were confirmed by surgical biopsy or resection with
lung as the primary site. MM diagnoses were based on
morphological criteria, supporting immunohistochemical
stains, mostly also with follow up surgical diagnosis, and
clinical follow up information and electron microscopy
examination in some cases. Paraffin cell blocks of effu-
sions were retrieved from department archives and 4-lm
thick sections were cut on charged slides and submitted
for immunostaining procedures following the manufac-
turer’s suggested condition with optimization for each
individual antibody. Immunostains using antibodies for
WT-1, p63, mesothelin, and MOC31 were performed on
all cases in this cohort, and in addition, all ADC, SCC
and a few MM cases were also stained with antibodies
against cytokeratin (CK5/6 and CK903). The detailed in-
formation of antibodies, antigen retrieval, and conditions
for each antibody’s detection methods was listed on Ta-
ble I. The immunocytochemical stains were performed on
the DAKO Auto-stainer at room temperature with final
DAB chromogen reaction for 5 min. Nuclear stains by
WT-1 and p63 antibody were considered positive while
membranous/cytoplasm stain with MOC31, mesothelin,
and cytokeratin (K903 and CK5/6) were considered posi-
tive. The final score on each case was recorded as either
negative (<10% of the tumor cells positive) or positive
(>10% of the tumor cells positive) staining similar to our
previous study.21 All scores were obtained blindly and
independently from all participating cytopathologists and
scoring differences were resolved before a consensus
score was given to any case.
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Statistical analysis was performed using a two-sided v2
test and a P value of less than 0.05 was considered signif-
icant.
Results
A cohort of 43 malignant effusions consisting of ADC
(10 cases), SCC (15 cases), and MM (18 cases) were
included for the study. The mean ages for the three
groups were 72, 72, and 64 years for ADC, SCC, and
MM groups, respectively. There was a male predomi-
nance among the three groups of patients: ADC (all male,
10), SCC (13 male and 2 female), and MM (13 male and
5 female). All of the ADC (10/10) and SCC (14/15) had
lung as the primary site confirmed with biopsy or resec-
tion while most of the MM were pleural based (16/18).
The antibody against p63 stained 80% SCC, 30%
ADC, but 0% MM cases (Table II). Most of the SCC had
intense nuclear stain (Fig. C-1, top row, middle column),
while most of the ADC were negative (Fig. C-1, top row,
right column) with only a few cases having tumor cells
stained with weak to moderate intensity, and no tumor
cells in MM stained with this antibody (Fig. C-1, top
row, left column). The difference between MM and SCC
was very dramatic (0% vs. 80%) while the difference
between MM and ADC, or ADC and SCC was also statis-
tically significant (Table II). Antibody against WT-1
reacted to 100% MM with intense nuclear stain but did
not stain any of the ADC or SCC, although scattered
background reactive/benign mesothelial cells were marked
with this antibody (Table II, Fig. C-1, second row).
MOC31 and antibody against mesothelin displayed a sim-
ilar trend in staining ADC, SCC. and MM cases with a
predominant membranous stain pattern (Fig. C-1, third
and forth row). MOC31 stained 100% ADC, 67% SCC,
but only 35% MM cases (Table II). The positive reactions
to this antibody between the following pairs, ADC versus
SCC (100% vs. 67%, P ¼ 0.013) and SCC versus MM
(67% vs. 35%, P ¼ 0.056), although different, had too
much overlap for this antibody to be useful for differen-
tial diagnosis. There might be a utility of this antibody in
differentiating ADC from MM (100% vs. 35%, P <
0.00001). Similarly, antibody against mesothelin also
stained 100% ADC, but only 60% SCC and 47% MM
cases (ADC vs. SCC, P ¼ 0.0056, ADC vs. MM, P ¼
0.0007, SCC vs. MM, P ¼ 0.46, Table II). As the above
tested antibodies did not show much value in discriminat-
ing between ADC and SCC, antibodies for cytokeratins
(K903 and CK5/6, Fig. C-1, bottom two rows) were
included to stain ADC and SCC cases in order to sepa-
rate the two groups. The results showed that the SCC
cases were all positive for CK5/6 (100%) with a cyto-
plasmic stain pattern (Fig. C-1) and ADC cases were
rarely positive (10%), significantly different by statisti-
cal analysis (Table II). The stain for K903 was positive
in all the SCC (100%) with a cytoplasmic stain pattern,
but was also positive in almost half of the ADC (40%)
cases (Table II). MM also stained positive for those two
cytokeratin stains in the limited number of cases we
tested in this cohort (Fig. C-1, first column, last two
rows).
Table I. Antibodies and Detection Conditions
Antibody (clone) names and vendors 18 Ab, dilution and time 28 Ab, time 38 streptavidin label
Wilm’s tumor 1 (WT-1), Cell Marque Corporation, Hot Springs, AR 1:50, 300 300 n/a
p63 (Ab-1), LabVision, Freemont, CA 1:100, 150 450 300
MOC31(ERA), DAKO, Carpinteria, CA 1:30, 300 300 n/a
Mesothelin (5B2), Novocastra Lab. Newcastle Upon Tyne, UK 1:100, 300 600 n/a
Cytokeratin-K903, DAKO, Carpinteria, CA 1:100, 300 300 300
Cytokeratin-CK5/6, Chemicon International, Temecula, CA 1:100, 300 300 300
Antigen retrieval: 1. 10 min microwave with citrate buffer, pH 6.0; 2. 10 min cooling; 3. 15 min tap water wash.
Table II. Comparison Among Three Tumor Types for Different Antibodies
Positive cases (%) for each antibody
Tumor Total p63 WT-1 MOC31 Mesothelin K903 CK5/6
ADC 10 3 (30) 0 (0) 10 (100) 10 (100) 4 (40) 1 (10)
SCC 15 12 (80) 0 (0) 10 (67) 9 (60) 15 (100) 15 (100)
MM 18 0 (0) 18 (100) 6 (35a) 8 (47a) b b
P-values
ADC vs. SCC 0.0124 n/a 0.013 0.0056 0.0001 <0.00001
ADC vs. MM 0.0047 <0.00001 <0.00001 0.0007 n/a n/a
SCC vs. MM <0.00001 <0.00001 0.056 0.46 n/a n/a
a17 MM cases were stained for those two antibodies.
bOur previous publication had demonstrated that MM were positive for K903 and CK5/621 and a few MM cases stained in current series were also positive.
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Fig. C-1. Composite of representative images of MM, SCC, and ADC stained with each antibody (all at 403 magnification).
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Discussion
In this report, we tested the utility of a panel of immuno-
stains including WT-1, p63, MOC31, mesothelin, and cyto-
keratins (K903 and CK5/6) in malignant effusions (mostly
pleural) consisting of ADC, SCC, and MM. We showed
that WT-1 was most useful in differentiating MM from ei-
ther SCC or ADC of lung origin. MM cases were 100%
positive for WT-1 while none of the ADC or SCC was pos-
itive. The sensitivity and specificity were both 100%. We
demonstrated that WT-1 has comparable, if not higher,
specificity and sensitivity for mesothelial cells in cytological
specimens, mainly pleural effusions, to that of the most fre-
quently used positive mesothelial marker, calretinin.21
Although the number of cases in our cohort was small, our
results did confirm WT-1’s utility in effusions as a positive
mesothelial marker, which had been demonstrated in biopsy
specimens.2,9 Like calretinin, it does not differentiate MM
from benign/reactive mesothelial cells, thus has no utility in
such a setting. Another cautionary note is that ADC and
SCC cases in our cohort are of lung origin from predomi-
nantly male patients, thus breast and ovarian carcinoma are
not in the differential diagnosis and the conclusion does not
apply to them, as it has been shown that WT-1 is positive
in serous carcinoma of ovarian surface origin.22
Antibody against p63 stained a significant percentage
of SCC cases, a much lower percentage of ADC, and
none of the MM. Our result supports the utility of p63 in
pleural effusions as a marker in distinguishing lung SCC
from MM. Using WT-1 and p63 stains, most of the time,
we could reliably separate MM (positive for WT-1 and
negative for p63) from lung SCC and ADC in malignant
pleural effusions. This finding was similar to what others
had reported in pleural biopsies of epithelioid MM and
lung SCC.9 although in our cohort the percentage of p63
positive SCC was slightly lower.
On the other hand, our results that MOC31 stained
100% of ADC, 67% of SCC, and 35% of MM made it
not a very useful marker, although used as part of a panel
of markers it might be helpful in distinguishing ADC
from MM. In our study, MOC31 stained small but sig-
nificant numbers of MM cases, somewhat different
from others’ findings which showed MOC31 as a positive
marker for ADC or SCC (with 95–97% sensitivity and
93–100% specificity) and a negative marker for MM (7%
positive).9,14 By the same token, our anti-mesothelin stain
pattern of 100% positive for ADC, 60% for SCC, and
47% for MM was in sharp contrast to some published
results which showed positive stain in all MM (100%)
and much lower positive stain for lung ADC (40%) and
SCC (27%) but slightly higher percentage of non-pulmo-
nary ADC (50%).9,11,23 However, some of the recent pub-
lications demonstrated that mesothelin was not a very spe-
cific or sensitive marker for meosthelioma (one study has
a sensitivity of 73% and specificity of 55%13), although
in those studies mesothelioma was stained with a much
higher percentage than ADC.9,13,24 One Japanese group
analysing 90 epithelioid MM and 51 lung ADC showed
similar positive stain by mesothelin antibody in MM
(77%) and ADC (69%), which further suggest mesothelin
might not be a good marker for mesothelioma at all.24
Our results suggest that MOC31 and mesothelin stains
are not very useful in pleural effusions for our differential
diagnosis, even though the differences among the three
groups are statistically significant. Explanations for
MOC31 and mesothelin stain difference between ours and
that of the others could be many, including but not lim-
ited to: different specimen fixation conditions of surgical
and cytological samples, different antigen retrieval meth-
ods, and different primary and secondary antibody or
detection conditions. The mesothelin antibody we used is
the same as others have used.13 The pre-treatment for
antigen retrieval and dilution of primary antibody were
similar, but we used a different detection system (DAKO
vs. Ventana).13 In addition, we had ADC of lung primary
while it was more diverse groups of adenocarcinoma in
others’ cohort.13 Furthermore, different definitions of a
positive, e.g. different percentage of positive tumor cells
stained to be scored as positive or in some studies only
membrane stain, while in others, as was in our case,
either membranous and cytoplasm stain of mesothelin
were considered positive, may contribute to inconsistency
in positive rates. We don’t have a plausible explanation
for the discrepancy observed on anti-mesothelin stain,
except it strongly suggests that it is prudent to have each
antibody validated for its performance in the individual
laboratory before universal application.
In our cohort, in order to differentiate ADC from SCC,
cytokeratin stains (K903 and CK5/6) were necessary as
all of the SCC were positive for those two-antibody
stains, while fewer cases of ADC were positive for them.
Another stain, TTF1, demonstrated by other’s published
data and also in our experience, can help separating lung
ADC from SCC.25 It is worth mentioning that MM also
stained positive for those two cytokeratin stains in the
limited number of cases we tested in this cohort (data not
shown) and in our previously published work.21 There-
fore, the utility of K903 and CK5/6 in separating ADC
from SCC is valid only when MM has been ruled out.
In conclusion, MM can be separated from either SCC
or ADC by its WT-1 positive and p63 negative stains
when differential diagnoses of malignant effusions involv-
ing lung carcinoma (either ADC or SCC) and MM. p63 is
more likely to be positive in SCC than ADC, but cytoker-
atin, especially CK5/6 is a better marker in separating
SCC from ADC when MM has been ruled out. MOC31
might have limited value in differentiating ADC from
MM in conjunction with other markers, but it is not use-
ful in differentiating between SCC and ADC or MM and
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SCC other than that negative MOC31 stain can exclude
lung ADC. Mesothelin, in our cohort, is not a useful marker
in the differential diagnosis of ADC, SCC and MM.
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